Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy-Reference-Cited by-同舟云学术

Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy

Published:2023-10 Issue:6 Volume:20 Page:1707-1722
ISSN:1878-7479
Container-title:Neurotherapeutics
language:en
Short-container-title:Neurotherapeutics

Author:

Freeman Sean A.^ORCID,Lemarchant Bruno,Alberto Tifanie,Boucher Julie,Outteryck Olivier,Labalette Myriam,Rogeau Stéphanie,Dubucquoi Sylvain,Zéphir Hélène

Publisher

Elsevier BV

Subject

Pharmacology (medical),Neurology (clinical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s13311-023-01446-5.pdf

Reference52 articles.

1. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial;Bar-Or;Ann Neurol,2008

2. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis;Hauser;N Engl J Med.,2008

3. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis;Hauser;N Engl J Med,2017

4. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study;Bar-Or;Neurology,2018

5. Ofatumumab versus teriflunomide in multiple sclerosis;Hauser;N Engl J Med,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy;Drug Design, Development and Therapy;2024-07

2. Multiple sclerosis treatment review for primary care providers;The Nurse Practitioner;2024-06-25

3. Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy;Revue Neurologique;2024-04